BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsumura M, Hatakeyama S, Koni I, Mabuchi H, Muramoto H. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron. 1996;72:574-578. [PMID: 8730424 DOI: 10.1159/000188942] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Ahmad S. L‐Carnitine in Dialysis Patients. Seminars in Dialysis 2001;14:209-17. [DOI: 10.1046/j.1525-139x.2001.00055.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
2 Yee J. L-carnitine for anemia in hemodialysis patients: a last resort. Clin J Am Soc Nephrol 2012;7:1746-8. [PMID: 23085730 DOI: 10.2215/CJN.09920912] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Schreiber B. Levocarnitine and Dialysis: A Review. Nutr Clin Pract 2017;20:218-43. [DOI: 10.1177/0115426505020002218] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
4 Mercadal L, Coudert M, Vassault A, Pieroni L, Debure A, Ouziala M, Depreneuf H, Fumeron C, Servais A, Bassilios N, Bécart J, Assogba U, Allouache M, Bouali B, Luong N, Dousseaux MP, Tezenas-du Montcel S, Deray G. L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol 2012;7:1836-42. [PMID: 22935844 DOI: 10.2215/CJN.12431211] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
5 Sotirakopoulos N, Athanasiou G, Tsitsios T, Mavromatidis K. The influence of l-carnitine supplementation on hematocrit and hemoglobin levels in patients with end stage renal failure on CAPD. Ren Fail. 2002;24:505-510. [PMID: 12212830 DOI: 10.1081/jdi-120006777] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
6 . Anemia. Manual of Clinical Dialysis. Boston: Springer US; 2009. pp. 199-209. [DOI: 10.1007/978-0-387-09651-3_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Volti GL, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011; 17(39): 4414-4420 [PMID: 22110268 DOI: 10.3748/wjg.v17.i39.4414] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
8 Zhang ZH, Vaziri ND, Wei F, Cheng XL, Bai X, Zhao YY. An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. Sci Rep 2016;6:22151. [PMID: 26903149 DOI: 10.1038/srep22151] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 16.0] [Reference Citation Analysis]
9 Matera M, Bellinghieri G, Costantino G, Santoro D, Calvani M, Savica V. History of L-carnitine: Implications for renal disease. Journal of Renal Nutrition 2003;13:2-14. [DOI: 10.1053/jren.2003.50010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
10 Murphy WJA, Steiber A, Connery GC, Carder J, Spry L, Hoppel C. Altered carnitine metabolism in dialysis patients with reduced physical function may be due to dysfunctional fatty acid oxidation. Nephrology Dialysis Transplantation 2012;27:304-10. [DOI: 10.1093/ndt/gfr334] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
11 Polaschegg H, Levin NW. Hemodialysis machines and monitors. In: Hörl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF, editors. Replacement of Renal Function by Dialysis. Dordrecht: Springer Netherlands; 2004. pp. 325-449. [DOI: 10.1007/978-1-4020-2275-3_14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
12 Maruyama T, Higuchi T, Yamazaki T, Okawa E, Ando H, Oikawa O, Inoshita A, Okada K, Abe M. Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia. Cardiorenal Med 2017;7:188-97. [PMID: 28736559 DOI: 10.1159/000462983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
13 Reuter SE, Faull RJ, Evans AM. L-carnitine supplementation in the dialysis population: are Australian patients missing out? Nephrology (Carlton) 2008;13:3-16. [PMID: 18199095 DOI: 10.1111/j.1440-1797.2007.00817.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
14 Guieu R, Brunet P, Sampol J, Bechis G, Fenouillet E, Mege JL, Capo C, Vitte J, Ibrahim Z, Carrega L, Lerda D, Rochat H, Berland Y, Dussol B. Adenosine and hemodialysis in humans. J Investig Med 2001;49:56-67. [PMID: 11217148 DOI: 10.2310/6650.2001.34091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
15 Steiber AL, Weatherspoon LJ, Spry L, Davis AT. Serum carnitine concentrations correlated to clinical outcome parameters in chronic hemodialysis patients. Clin Nutr 2004;23:27-34. [PMID: 14757390 DOI: 10.1016/s0261-5614(03)00085-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Sun Y, Liu G, Li X, Shi Y, Guan G. L -Carnitine inhibits eryptosis induced by uremic serum and the related mechanisms. Renal Failure 2015;37:1050-6. [DOI: 10.3109/0886022x.2015.1052977] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Hedayati SS. Dialysis-related carnitine disorder. Semin Dial 2006;19:323-8. [PMID: 16893411 DOI: 10.1111/j.1525-139X.2006.00180.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
18 Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V. Carnitine and hemodialysis. Am J Kidney Dis 2003;41:S116-22. [PMID: 12612967 DOI: 10.1053/ajkd.2003.50099] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
19 Bommer J. Saving erythropoietin by administering l-carnitine? Nephrology Dialysis Transplantation 1999;14:2819-21. [DOI: 10.1093/ndt/14.12.2819] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
20 Steiber AL, Davis AT, Spry L, Strong J, Buss ML, Ratkiewicz MM, Weatherspoon LJ. Carnitine Treatment Improved Quality-of-Life Measure in a Sample of Midwestern Hemodialysis Patients. JPEN J Parenter Enteral Nutr 2017;30:10-5. [DOI: 10.1177/014860710603000110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
21 Arduini A, Bonomini M, Clutterbuck EJ, Laffan MA, Pusey CD. Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients. Nephrol Dial Transplant 2006;21:2671-2. [PMID: 16611680 DOI: 10.1093/ndt/gfl155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
22 Kadiroglu AK, Yilmaz ME, Sit D, Kara IH, Isikoglu B. The Evaluation of Postdialysis l -Carnitine Administration and Its Effect on Weekly Requiring Doses of rHuEPO in Hemodialysis Patients. Renal Failure 2009;27:367-72. [DOI: 10.1081/jdi-65296] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
23 Calvani M, Benatti P, Mancinelli A, D'Iddio S, Giordano V, Koverech A, Amato A, Brass EP. Carnitine replacement in end-stage renal disease and hemodialysis. Ann N Y Acad Sci 2004;1033:52-66. [PMID: 15591003 DOI: 10.1196/annals.1320.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
24 Reuter SE, Faull RJ, Ranieri E, Evans AM. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. Nephrol Dial Transplant. 2009;24:990-996. [PMID: 18987259 DOI: 10.1093/ndt/gfn588] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
25 Hoppel C. The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis. 2003;41:S4-12. [PMID: 12751049 DOI: 10.1016/s0272-6386(03)00112-4] [Cited by in Crossref: 140] [Cited by in F6Publishing: 72] [Article Influence: 7.8] [Reference Citation Analysis]
26 Macdougall IC. Hyporesponsiveness to Anemia Therapy—What are we Doing Wrong? Perit Dial Int 2001;21:225-30. [DOI: 10.1177/089686080102103s40] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
27 Golper TA, Goral S, Becker BN, Langman CB. l-carnitine treatment of anemia. American Journal of Kidney Diseases 2003;41:S27-34. [DOI: 10.1016/s0272-6386(03)00114-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
28 Mahmoud T, Borgi L. The Interplay Between Nutrition, Metabolic, and Endocrine Disorders in Chronic Kidney Disease. Semin Nephrol 2021;41:180-8. [PMID: 34140096 DOI: 10.1016/j.semnephrol.2021.03.012] [Reference Citation Analysis]
29 Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007;12:321-30. [PMID: 17635745 DOI: 10.1111/j.1440-1797.2007.00810.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 73] [Article Influence: 6.6] [Reference Citation Analysis]
30 Berns JS, Mosenkis A. Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis. Hemodialysis International 2005;9:7-22. [DOI: 10.1111/j.1492-7535.2005.01113.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
31 Thomas S, Fischer F, Mettang T, Pauli-magnus C, Weber J, Kuhlmann U. Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: A double-blind randomized trial. American Journal of Kidney Diseases 1999;34:678-87. [DOI: 10.1016/s0272-6386(99)70393-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
32 Takashima H, Maruyama T, Abe M. Significance of Levocarnitine Treatment in Dialysis Patients. Nutrients 2021;13:1219. [PMID: 33917145 DOI: 10.3390/nu13041219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Nikolaos S, George A, Telemachos T, Maria S, Yannis M, Konstantinos M. EFFECT OF L-CARNITINE SUPPLEMENTATION ON RED BLOOD CELLS DEFORMABILITY IN HEMODIALYSIS PATIENTS. Renal Failure 2009;22:73-80. [DOI: 10.1081/jdi-100100853] [Cited by in Crossref: 31] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
34 Mechanick JI, Brett EM, Chausmer AB, Dickey RA, Wallach S, Bergman DA, Garber JR, Hamilton CR, Handelsman Y, Holdy KE, Kukora JS, Levy P, Palumbo PJ, Petak SM, Poretsky L, Rabito P, Rettinger HI, Rodbard HW, Service FJ, Shankar TP, Hensrud DD. American Association of Clinical Endocrinologists Medical Guidelines for the Clinical Use of Dietary Supplements and Nutraceuticals. Endocrine Practice 2003;9:417-70. [DOI: 10.4158/ep.9.5.417] [Cited by in Crossref: 50] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]